参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Bladder Cancer Version 1.2019-December 20, 2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.American Urological Association.Diagnosis and treatment of nonmuscle invasive bladder cancer: AUA/SUO guideline.2016.
4.Yuan H, Qiu J, Liu L, et al.Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with nonmuscle invasive bladder cancer: a metaanalysis of randomized controlled trials.PLoS One 2013, 8: e74142.
5.Kamat AM, Cookson M, Witjes JA, et al.The impact of blue light cystoscopy with hexaminolevulinate(HAL)on progression of bladder cancer - A new analysis.Bladder Cancer 2016, 2: 273-278.
6.Xiong Y, Li J, Ma S, et al.A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.PLoS One 2017, 12: e0170819.
7.Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, et al.Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.Eur Urol 2018, 73: 226-232.
8.Vashistha V, Quinn DI, Dorff TB, et al.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.BMC Cancer 2014, 14: 966.
9.Galsky MD, Stensland KD, Moshier E, et al.Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer.J Clin Oncol 2016, 34: 825-832.
10.Zaghloul MS, Christodouleas JP, Smith A, et al.Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.JAMA Surg 2017: e174591.
11.Chang SS, Bochner BH, Chou R, et al.Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.J Urol 2017, 198: 552-559.(https://www.daowen.com)
12.Giacalone NJ, Shipley WU, Clayman RH, et al.Longterm Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.Eur Urol 2017, 71: 952-960.
13.Haque W, Verma V, Butler EB, et al.Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base.Bladder Cancer 2017, 3: 283-291.
14.Dayyani F, Pettaway CA, Kamat AM, et al.Retrospective analysis of survival outcomes and the role of cisplatinbased chemotherapy in patients with urethral carcinomas referred to medical oncologists.Urol Oncol 2013, 31: 1171-1177.
15.Dayyani F, Hoffman K, Eifel P, et al.Management of advanced primary urethral carcinomas.BJU Int 2014, 114: 25-31.
16.Gakis G, Schubert T, Alemozaffar M, et al.Update of the ICUDSIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.World J Urol 2017, 35: 327-335.
17.Sharma P, Retz M, Siefker-Radtke A, et al.Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275): a multicentre, single-arm, phase 2 trial.Lancet Oncol 2017, 18: 312-322.
18.Humphrey PA, Moch H, Cubilla AL, et al.The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: Prostate and bladder tumours.Eur Urol 2016, 70: 106-119.
19.Seisen T, Peyronnet B, Dominguez-Escrig JL, et al.Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel.Eur Urol 2016, 70: 1052-1068.
20.Dimarco DS, Dimarco CS, Zincke H, et al.Surgical treatment for local control of female urethral carcinoma.Urol Oncol 2004, 22: 404-409.
21.Dayyani F, Pettaway CA, Kamat AM, et al.Retrospective analysis of survival outcomes and the role of cisplatinbased chemotherapy in patients with urethral carcinomas referred to medical oncologists.Urol Oncol 2013, 31: 1171-1177.